Welcome to our dedicated page for Ispire Technology news (Ticker: ISPR), a resource for investors and traders seeking the latest updates and insights on Ispire Technology stock.
Ispire Technology Inc. develops, commercializes, sells and distributes branded e-cigarettes and cannabis vaping products. Its e-cigarette products are marketed under the Aspire name through a global distribution network, while cannabis vaping hardware is sold under the Ispire brand, primarily through original design manufacture relationships with other cannabis vapor companies.
Recurring ISPR news includes quarterly financial results, cash and working-capital updates, product and customer activity, manufacturing and distribution developments, and regulatory technology initiatives for electronic nicotine delivery systems. Coverage also includes IKE Tech, a joint venture involving Ispire, and its age-gating, authentication and point-of-use compliance technology tied to FDA discussions, PMTA submissions and flavored ENDS regulation.
Ispire Technology (ISPR) reported Q4 2026 revenue of $26.7 million, up 32.5% year-over-year and 43% sequentially, for the quarter ended June 30, 2026.
Q4 gross profit was $1.7 million with gross margin of 6.3%, down from 12.3% a year earlier, due in part to inventory impairments. Q4 operating expenses fell 11.1% to $15.2 million, and net loss narrowed to $13.8 million, or $(0.24) per share. Full-year 2026 revenue declined 24.7% to $96.0 million, with lower cannabis vaping hardware sales in the U.S. and reduced vaping product sales in Europe and Asia-Pacific.
For fiscal 2026, gross margin decreased to 12.8%, while total operating expenses fell 26% to $44.9 million, driving an improved net loss of $33.2 million and Adjusted EBITDA loss of $4.0 million. Net cash used in operating activities improved to $0.6 million. As of June 30, 2026, cash was $19.3 million and stockholders’ equity stood at a deficit of $29.2 million. Management no longer gives a firm timeframe for achieving cash-flow-positive performance, citing ongoing Malaysia facility investments.
Ispire Technology (ISPR) will hold an earnings conference call at 8:00 a.m. ET on Wednesday, September 16, 2026, to discuss financial results for its fiscal fourth quarter and full year ended June 30, 2026.
Participants can join by dialing 1-877-451-6152 (United States) or 1-201-389-0879 (international) and requesting the “Ispire Technology Call.” The call will also be webcast live at https://viavid.webcasts.com/starthere.jsp?ei=1774514&tp_key=560753d6f6, with attendees advised to log in 15 minutes early for registration and software setup.
A replay will be available until 11:59 p.m. ET on Wednesday, September 30, 2026, by dialing 1-844-512-2921 or +1-412-317-6671 and using passcode 13762496.
Ispire Technology (NASDAQ: ISPR) appointed Steven Przybyla as President, effective immediately, while he continues as Chief Legal Officer and Secretary. The company said this gives Ispire a senior U.S.-based executive focused on investor communications, regulatory strategy and its growth plan, working closely with the CEO and CFO on material investor relations matters.
According to Ispire, the move is intended to ensure continuity of U.S. leadership and provide shareholders, analysts and prospective investors with a clear, consistent point of contact, including for its compliance-driven technology platform and the IKE Tech joint venture. Przybyla has more than 10 years’ experience in nicotine and tobacco product regulation and has held leadership roles at several regulated nicotine and cannabis businesses.
Ispire Technology (NASDAQ: ISPR) formed a strategic joint venture with Shandong Jincheng Pharmaceutical Group to manufacture and commercialize nicotine pouch products. The deal marks Ispire’s entry into the fast-growing oral nicotine category, expanding beyond vaping hardware into a segment projected to exceed $40 billion by 2033.
Jincheng Pharma will provide manufacturing equipment, expertise, and pouch materials, while Ispire contributes precision dosing know-how, regulatory compliance, and global distribution. Initial production is expected to leverage existing commercial relationships and support Ispire’s broader international reduced-risk nicotine platform strategy.
Ispire Technology (Nasdaq: ISPR) reported fiscal Q3 2026 results for the quarter ended March 31, 2026. Revenue was $18.7M, gross profit $2.0M, and net loss $9.5M (‑$0.17/share). Cash rose sequentially by $468,000 to $18.0M and working capital was $0.9M. Management cited Malaysia manufacturing live, Vapor ODM ramp in July 2026, and future age‑gating and G‑Mesh opportunities targeting multi‑billion markets.
Ispire Technology (NASDAQ: ISPR) will host its fiscal third quarter 2026 earnings conference call at 8:00 am ET on Thursday, May 7, 2026 to discuss results for the quarter ended March 31, 2026.
Dial-in numbers, a live webcast link, and replay details with passcode are provided for listeners and investors.
IKETech (NASDAQ: ISPR) won two honors at the Age Assurance Industry Awards on April 15, 2026, receiving Privacy-Centric Age Assurance Solution of the Year and a Highly Commended mention for Innovation in Age Assurance Technology.
The company cited independent expert judging and highlighted supporting milestones: a Human Factors Validation Study, SOC 2 Type II certification, and an FDA PMTA submission.
Ispire Technology (NASDAQ: ISPR) joint venture IKE Tech engaged the FDA Center for Tobacco Products on April 9, 2026 to present point-of-use compliance technologies for ENDS, including its patented Human Identity Token (HIT), biometric age-gating, blockchain product authentication, and AI governance.
IKE Tech said its standalone component PMTA for interoperable age-gating was accepted by FDA in June 2025 and a Human Factors Validation Study showed 100% prevention of underage device activation.
IKE Tech (NYSE:ISPR) welcomed the FDA's March 2026 draft guidance that, for the first time, explicitly recognizes continuous, device-level age verification (Device Access Restrictions) as a factor in PMTA APPH determinations.
IKE Tech highlights its April 2025 component PMTA, a validated BLE/biometric/blockchain age-gating system with a multi-center human factors study showing 100% successful verification (n=101) and 0% underage activation.
Ispire (NASDAQ: ISPR) says FDA draft guidance on flavored ENDS recognizes device-level age verification and may unlock a $50 billion U.S. total addressable market by enabling lawful transition of primarily illicit flavored vape sales into a compliant ecosystem. Ispire's 40% JV, IKE Tech, claims $5M–$20M annual SaaS revenue per customer and says it filed the first component PMTA for continuous, blockchain-enabled age-gating technology with human-factors results cited as 100% underage prevention and 100% demographic accuracy.